The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study.
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Shinji Itoh
No Relationships to Disclose
 
Ryosuke Tateishi
Honoraria - Abbvie; AstraZeneca; Bayer Yakuhin; Daiichi Sankyo; Eisai; Fujifilm; GE Healthcare; Gilead Sciences; Merck Sharp & Dohme; Otsuka; Shionogi; Sumitomo Dainippon
Consulting or Advisory Role - Bayer Yakuhin; Shionogi
Research Funding - Wako Diagnostics
 
Tatsuya Yamashita
Speakers' Bureau - Bayer; Chugai Pharma; Eisai; Lilly; Sumitomo Dainippon Pharma Oncology; Takeda
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Incyte; Lilly; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst)
 
Naoya Kato
Speakers' Bureau - Abbott; Abbvie; Aska Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb Company; Chugai Pharma; Covidien; Daiichi Sankyo Co.,Ltd.; EA Pharma; Eisai; Fujifilm; Gilead Sciences; Kowa; Lilly Japan; Mitsubishi Tanabe Pharma; Miyarisan pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Mylan; Nichi-iko; Nippon Kayaku; Nobelpharma; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Takeda; Tsumura & Co.; Zeria Pharmaceutical
Research Funding - Abbvie (Inst); Asahi Kasei (Inst); Asahi Kasei (Inst); Aska Pharmaceutical Co.,Ltd. (Inst); Astellas Pharma (Inst); Boston Scientific (Inst); Chugai Pharma (Inst); Covidien (Inst); CYTLIMIC (Inst); Daiichi Sankyo co.,Ltd. (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); JIMRO (Inst); Kowa (Inst); Medicos Hirata (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Shionogi (Inst); Sumitomo Dainippon Pharma Co.,Ltd. (Inst); Takeda (Inst); Tsumura & Co. (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Merck; MSD; Mundipharma; OncoTherapy Science; Ono Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Masatoshi Kudo
Honoraria - Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Research Funding - Abbvie (Inst); Chugai/Roche; EA Pharma (Inst); Eisai (Inst); GE Healthcare; Otsuka (Inst); Taiho Pharmaceutical (Inst)